The New Techno-Eugenics: Germline Engineering and the End of Humanity
By Dan Cloer,
Vision [cites CGS' Richard Hayes]
| 07. 16. 2019
Our newfound power to manipulate the genes of our children compels the human community to address a foundational question: Will we use science and technology to further or to subvert the human species?
Fifteen thousand babies are born every hour, every day, around the world. About 3 percent, or 450 individuals, are twins. In November 2018, a very special set of twins were born in China. Named Nana and Lulu, the sisters were the first humans to be genetically altered using CRISPR, the gene-editing system developed from bacteria.
A codiscoverer and pioneer in the application of CRISPR technology to genome editing, Berkeley scientist Jennifer Doudna, told Vision in 2016, “The big-picture view is that we have the tools to change our DNA and change the things that we are passing on to future generations. And now we can make those decisions. That is a profound thought.”
Continuing, Doudna noted general agreement among the scientific community that there should be “broad societal consensus before we use this technology in any clinical application in the human germline. But how do you define ‘broad societal consensus’? That remains to be seen; it was not the end of the conversation but the beginning.”
But conversation and consensus have been overwhelmed by the reality of Nana and...
Related Articles
By Mariella Bodemeier Loayza Careaga, The Scientist | 03.15.2024
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions of microscopic beings...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Carol Cardona and Michelle Kromm, Scientific American | 03.11.2024
By Nada Hassanein, New Jersey Monitor | 03.14.2024
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...